We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+0.45%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$520M
AUM Growth
+$3.52M
(+0.68%)
Cap. Flow
+$20.7M
Cap. Flow
% of AUM
3.98%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
129
New
9
Increased
50
Reduced
34
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$10.3M |
| 2 |
TSVT
2seventy bio
TSVT
|
+$5.44M |
| 3 |
Vera Therapeutics
VERA
|
+$4.63M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$4.57M |
| 5 |
Treace Medical Concepts
TMCI
|
+$4.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$8.88M |
| 2 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$5.52M |
| 3 |
iRhythm Holdings
IRTC
|
+$4.01M |
| 4 |
Arrowhead Research
ARWR
|
+$3.87M |
| 5 |
HealthEquity
HQY
|
+$3.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.06% |
| 2 | Industrials | 4.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Regeneron Pharmaceuticals
REGN
$78.2B
| $2.29M | 0.44% |
2,790
+80
| +3% | +$60.3K |
|
|
RETA
77
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.27M | 0.44% |
+25,000
| New | +$1.47M |
|
78
Vaxcyte
PCVX
$7.73B
| $2.25M | 0.43% |
60,000
| – | – |
|
79
Gilead Sciences
GILD
$163B
| $2.13M | 0.41% |
25,700
-350
| -1% | -$29K |
|
80
Vertex Pharmaceuticals
VRTX
$119B
| $2.09M | 0.4% |
6,619
-400
| -6% | -$120K |
|
81
Altimmune
ALT
$583M
| $2.02M | 0.39% |
479,100
+136,600
| +40% | +$1.62M |
|
82
Beam Therapeutics
BEAM
$2.67B
| $1.94M | 0.37% |
63,500
| – | – |
|
83
Humana
HUM
$45B
| $1.74M | 0.33% |
3,575
| – | – |
|
|
GBIO
84
DELISTED
Generation Bio
GBIO
| $1.66M | 0.32% |
38,507
+11,128
| +41% | +$538K |
|
85
BioAtla
BCAB
$5.41M
| $1.46M | 0.28% |
10,860
+8,094
| +293% | +$1.46M |
|
|
MRSN
86
DELISTED
Mersana Therapeutics
MRSN
| $1.41M | 0.27% |
+13,723
| New | +$1.93M |
|
87
AstraZeneca
AZN
$245B
| $1.39M | 0.27% |
10,005
| – | – |
|
88
4D Molecular Therapeutics
FDMT
$527M
| $1.38M | 0.26% |
80,029
+26,193
| +49% | +$509K |
|
|
PNT
89
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $1.33M | 0.26% |
182,668
-2,610
| -1% | -$19.4K |
|
90
Atea Pharmaceuticals
AVIR
$369M
| $1.28M | 0.25% |
380,850
+99,447
| +35% | +$403K |
|
91
Annexon
ANNX
$860M
| $1.26M | 0.24% |
+326,806
| New | +$1.8M |
|
|
ITOS
92
DELISTED
iTeos Therapeutics
ITOS
| $1.2M | 0.23% |
88,373
+30,611
| +53% | +$548K |
|
93
PMV Pharmaceuticals
PMVP
$59.7M
| $1.19M | 0.23% |
+250,469
| New | +$1.76M |
|
|
ONC
94
BeOne Medicines Ltd
ONC
$32.6B
| $1.19M | 0.23% |
5,510
-470
| -8% | -$113K |
|
|
EXAI
95
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $1.11M | 0.21% |
210,303
-54,795
| -21% | -$372K |
|
96
Scholar Rock
SRRK
$5.49B
| $1.08M | 0.21% |
134,569
-16,638
| -11% | -$169K |
|
97
Illumina
ILMN
$29.9B
| $1.05M | 0.2% |
4,647
-102
| -2% | -$20.9K |
|
|
EFTR
98
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $840K | 0.16% |
95,306
| – | – |
|
|
HZNP
99
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $644K | 0.12% |
5,900
-900
| -13% | -$99.5K |
|
100
Sanofi
SNY
$103B
| $484K | 0.09% |
8,900
| – | – |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Sectoral Asset Management held 129 positions worth $520M, up 0.68% from $517M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Sectoral Asset Management deployed $20.7M of net new capital in Q1 2023, opening 9 new positions and adding to 50 existing holdings. Its largest new stake was Mineralys Therapeutics: 613,233 shares worth $9.6M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was R1 RCM Inc. Common Stock, an estimated $5.52M trimmed.
- Sectoral Asset Management's largest Q1 2023 buy was Mineralys Therapeutics: 613,233 shares worth $9.6M.
- Sectoral Asset Management added most to Shockwave Medical, Inc. Common Stock in Q1 2023, an estimated $4.57M increase.
- Sectoral Asset Management's biggest Q1 2023 reduction was R1 RCM Inc. Common Stock, cutting an estimated $5.52M.
- Sectoral Asset Management fully exited Exelixis in Q1 2023, selling an estimated $8.88M.
- Sectoral Asset Management's ten largest holdings make up 24% of its $520M portfolio in Q1 2023.
- Sectoral Asset Management opened 9 new positions and closed 11 in Q1 2023.
- Sectoral Asset Management's portfolio value rose 0.68% quarter-over-quarter to $520M.
Based on Sectoral Asset Management's 13F filing for Q1 2023, filed 12 May 2023.